- Enter the acute kidney injury (AKI) onset date. If it is not documented, leave it blank and enter the discharge date.
- Confirm the assessment date (today by default) and tick what applies: dialysis at discharge, known chronic kidney disease (CKD), and any open concerns.
- Optional: enter a baseline and a latest creatinine, each with its unit and date, to see the change between them.
- Read the reassessment date, its status, and the follow-up checklist.
For adults with a documented AKI hospitalization. All computation runs in your browser; nothing you enter is stored, sent, or placed in the page address.
When to Use
Use it at discharge or at the first clinic contact after a hospital stay with AKI, to fix a date for reassessment and to make sure four things are not missed: kidney function, urine albumin, blood pressure and volume, and the medicine list. The 3-month point matters because kidney disease that persists beyond 3 months meets the time criterion for CKD.
What this tool does not do
It does not label a patient as recovered, derive an AKI stage, estimate risk, or tell anyone to start, stop or change a medicine. It is not for children, for patients still in hospital, or for kidney transplant recipients, who follow their transplant team's schedule.
Pearls & Pitfalls
Three months is the latest routine checkpoint, not the earliest
Earlier review is appropriate after severe AKI, with heart failure, with unresolved electrolyte problems, or when medicines were held and need a restart decision. Dialysis at discharge needs a nephrology-directed schedule from day one.
Measure urine albumin, not only creatinine
In the ASSESS-AKI cohort, a higher urine albumin-to-creatinine ratio (uACR) about 3 months after discharge was associated with later kidney disease progression (hazard ratio 1.53 per doubling, 95% CI 1.45 to 1.62). This is an association in a cohort; it cannot be converted into one patient's absolute risk.
Pitfalls
(1) Reading a creatinine that is still changing as an estimated glomerular filtration rate (eGFR). (2) Using a "baseline" measured during the acute illness. (3) Trusting creatinine after a long admission with muscle loss, where it can look better than kidney function is. (4) Diagnosing CKD before the 3-month time criterion is met.
Post-AKI Follow-Up Planner
Dates are handled as calendar dates. Leave a field blank if it is not documented; the planner shows unknowns as unknown.
Optional: creatinine change from baseline
Enter the AKI onset date, or the discharge date if onset is unknown.
⚕ A planning aid for clinicians. It gives no recovery designation, derived AKI stage, risk estimate, or medication instruction. Evaluate for CKD using established chronicity criteria.
Evidence & References
Rules
| Item | Rule |
|---|---|
| Reassessment date | AKI onset + 3 calendar months. A day that does not exist is moved to the last day of that month (August 31 → November 30). |
| Onset unknown | Discharge + 3 calendar months, labeled as an operational fallback and not as the guideline anchor. |
| Status | Days between the assessment date and the reassessment date. |
| Creatinine units | Converted once to mg/dL using 88.4 µmol/L per mg/dL; rounded only for display. |
| Change from baseline | Latest − baseline, and (latest − baseline) ÷ baseline × 100. Shown only with a positive baseline dated on or before the latest test. |
| Dialysis at discharge | Replaces the routine checklist with a clinician-directed dialysis-transition list. |
Source and strength
The 3-month reassessment is recommendation 2.3.4 of the Kidney Disease: Improving Global Outcomes (KDIGO) 2012 AKI guideline: evaluate patients 3 months after AKI for resolution, new onset, or worsening of pre-existing CKD. It is Not Graded. A KDIGO 2026 guideline on AKI and acute kidney disease was released as a public-review draft in 2026; this tool stays tied to the final 2012 text until that update is published.
Randomized evidence for a specific follow-up model is limited. In FUSION (71 randomized of 269 eligible), nephrologist follow-up did not change major adverse kidney events at 1 year (44% vs 43%), and most eligible patients declined in-person visits. In a 98-patient trial after stage 3 AKI, multidisciplinary care improved blood pressure control and lowered uACR at 12 months without a difference in eGFR. Both are small trials with process or surrogate outcomes.
References
- Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2(1):1-138. doi:10.1038/kisup.2012.1
- Hsu CY, Chinchilli VM, Coca S, et al. Post-acute kidney injury proteinuria and subsequent kidney disease progression: the ASSESS-AKI study. JAMA Intern Med. 2020;180(3):402-410. doi:10.1001/jamainternmed.2019.6390
- Silver SA, Adhikari NK, Bell CM, et al. Nephrologist follow-up versus usual care after an acute kidney injury hospitalization (FUSION): a randomized controlled trial. Clin J Am Soc Nephrol. 2021;16(7):1005-1014. doi:10.2215/CJN.17331120
- Thanapongsatorn P, Chaikomon K, Lumlertgul N, et al. Comprehensive versus standard care in post-severe acute kidney injury survivors, a randomized controlled trial. Crit Care. 2021;25(1):322. doi:10.1186/s13054-021-03747-7
- Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105(4S):S117-S314. doi:10.1016/j.kint.2023.10.018
